This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bedard, J.
Right arrow Articles by Rando, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bedard, J.
Right arrow Articles by Rando, R. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2000, p. 929-937, Vol. 44, No. 4
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Antiviral Properties of a Series of 1,6-Naphthyridine and 7,8-Dihydroisoquinoline Derivatives Exhibiting Potent Activity against Human Cytomegalovirus

Jean Bedard,1,* Suzanne May,1 Lucille L'Heureux,1 Thomas Stamminger,2 Alice Copsey,3 John Drach,4 John Huffman,5 Laval Chan,1 Haolun Jin,6 and Robert F. Rando1

Department of Virology, BioChem Pharma Inc., Laval, Quebec, Canada H7V 4A71; Institut für Klinische und Molekulare Virologie, 91054 Erlangen, Germany2; MRC Collaborative Center, Mill Hill, London, United Kingdom3; Department of Biologic and Materials Sciences, School of Dentistry, University of Michigan, Ann Arbor, Michigan 48109-10784; Institute for Antiviral Research, Utah State University, Logan, Utah 843225; and Gilead Sciences, Foster City, California 944046

Received 14 July 1999/Returned for modification 3 November 1999/Accepted 18 January 2000

A series of 1,6-naphthyridine (L. Chan, H. Jin, T. Stefanac, J. F. Lavallee, G. Falardeau, W. Wang, J. Bedard, S. May, and L. Yuen, J. Med. Chem. 42:3023-3025, 1999) and isoquinoline (L. Chan, H. Jin, T. Stefanac, W. Wang, J. F. Lavallee, J. Bedard, and S. May, Bioorg. Med. Chem. Lett. 9:2583-2586, 1999) analogues exhibiting a high level of anti-human cytomegalovirus (HCMV) activity were investigated in a series of studies aimed at better understanding the mechanism of action of some representatives of this class of compounds. In vitro antiviral profiling revealed that these compounds were active against a narrow spectrum of viruses, essentially the human herpesviruses and type 2 rhinovirus. In HCMV assays, a 39- to 223-fold lower 50% inhibitory concentration was obtained for compound A1 than for ganciclovir against strains AD 169 and Towne. In addition, ganciclovir, foscarnet, cidofovir, and BDCRB (2-bromo-5,6-dichloro-1-beta -D-ribofuranosylbenzimidazole)-resistant HCMV strains remained susceptible to 1,6-naphthyridines and 7,8-dihydroisoquinolines tested in this study, supporting the view that a novel mechanism of action could be involved. Drug combination studies showed a small but significant synergistic antiviral effect between compound B2 and ganciclovir. Cytotoxicity profiling of representative compounds under various cell growth conditions indicated a generally similar cytotoxic effect, relative to ganciclovir, in log-phase growing cells. However, in stationary cells, a relatively higher level of toxicity was observed than that for control compound. Effect of time of drug addition showed that the anti-HCMV activity of compound A1, ganciclovir, and cidofovir was lost at approximately the same time (72 h postinfection), indicating that the compound was affecting events at the early and late stage of virus replication. This interpretation is also supported by reduction of de novo synthesis of pp65 tegument protein and lack of any effect of the compound on viral adsorption. A reduction of the HCMV enhancer-promoter-directed luciferase expression was also observed in a stably transfected cell line when compound A1 was present at relatively high concentrations.


* Corresponding author. Mailing address: BioChem Pharma Inc., 275 Boul. Armand-Frappier, Laval, Quebec, Canada H7V 4A7. Phone: (514) 978-7864. Fax: (514) 978-7946. E-mail: bedardj{at}biochempharma.com.


Antimicrobial Agents and Chemotherapy, April 2000, p. 929-937, Vol. 44, No. 4
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • De Clercq, E. (2003). New inhibitors of human cytomegalovirus (HCMV) on the horizon. J Antimicrob Chemother 51: 1079-1083 [Full Text]  
  • Lenzo, J. C., Shellam, G. R., Lawson, C. M. (2001). Ganciclovir and Cidofovir Treatment of Cytomegalovirus-Induced Myocarditis in Mice. Antimicrob. Agents Chemother. 45: 1444-1449 [Abstract] [Full Text]